Amgen (AMGN) Reports Q4 Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Nasdaq hits record high as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mail_58cbc46cd3c33.jpg)
Get Alerts AMGN Hot Sheet
Price: $402.24 -0.2%
Revenue Growth %: +5.1%
Financial Fact:
Total operating expenses: 3.28B
Today's EPS Names:
VFS, PKE, More
Revenue Growth %: +5.1%
Financial Fact:
Total operating expenses: 3.28B
Today's EPS Names:
VFS, PKE, More
Join SI Premium – FREE
Amgen (NASDAQ: AMGN) reported its Q4 results, with EPS coming in at $4.36, beating the consensus estimate of $4.12. Revenue grew 3% year-over-year to $6.85 billion, slightly missing the consensus estimate of $6.88 billion, driven by increased Other Revenue from the Eli Lilly and Company COVID-19 manufacturing collaboration.
Total product sales for Q4 decreased 1% year-over-year. Unit volumes increased 7% but were more than offset by lower net selling price and lower inventory levels.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amgen (AMGN) Reiterated at Neutral by Cantor Fitzgerald
- Accenture (ACN) Tops Q4 EPS by 10c, Misses on Revenue; Offers Guidance
- ConAgra Brands (CAG) Tops Q1 EPS by 13c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
